Etentamig is one of several anti-BCMA T-cell engagers seeking attention at ASH.

Phase 2 data show why Merck took the lowest dose of zilo-V into phase 3.

Enzomenib might be the most promising agent so far, on a cross-trial basis.

The group presents data with bleximenib plus chemo, but looks behind Kura’s contender.

JNJ-89853413 is disclosed as the lead in the two companies' 2020 alliance.

And the company might one day follow Galapagos into decentralised manufacturing.

The group claims a seven-day vein-to-vein time is unique, and says why this matters.

Myelofibrosis projects and Merck's ROR1 ADC fight for attention at this month's conference.

A CD22-directed Car that has had several owners will next year deliver its most important dataset.